

TAGLN Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP6678a**Specification**

TAGLN Antibody (N-term) Blocking Peptide - Product Information

Primary Accession [Q01995](#)

TAGLN Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 6876

Other Names

Transgelin, 22 kDa actin-binding protein, Protein WS3-10, Smooth muscle protein 22-alpha, SM22-alpha, TAGLN, SM22, WS3-10

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6678a](/products/AP6678a) was selected from the N-term region of human TAGLN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

TAGLN Antibody (N-term) Blocking Peptide - Protein Information

Name TAGLN

Synonyms SM22, WS3-10

Function

Actin cross-linking/gelling protein (By similarity). Involved in calcium interactions and contractile properties of the cell that may contribute to replicative senescence.

Cellular Location

Cytoplasm.

TAGLN Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

TAGLN Antibody (N-term) Blocking Peptide - Images

TAGLN Antibody (N-term) Blocking Peptide - Background

TAGLN is a transformation and shape-change sensitive actin cross-linking/gelling protein found in fibroblasts and smooth muscle. Its expression is down-regulated in many cell lines, and this down-regulation may be an early and sensitive marker for the onset of transformation. A functional role of this protein is unclear.

TAGLN Antibody (N-term) Blocking Peptide - References

Zhao,L., Mod. Pathol. 22 (6), 786-796 (2009)Leguillette,R., Am. J. Respir. Crit. Care Med. 179 (3), 194-204 (2009)Yu,H., FASEB J. 22 (6), 1778-1789 (2008)